Brief: Inozyme Pharma Provides Update for Phase 1/2 Clinical Trials in ABCC6 Deficiency & ENPP1 Deficiency

Inozyme Pharma

12/04/2022 12:37

April 12 (Reuters) - Inozyme Pharma Inc  INZY.O :
    * INOZYME PHARMA PROVIDES UPDATE FOR PHASE 1/2 CLINICAL
TRIALS IN
ABCC6 DEFICIENCY AND ENPP1 DEFICIENCY
    * INOZYME PHARMA INC - FIRST PATIENT DOSED IN PHASE 1/2
CLINICAL
TRIAL IN ABCC6 DEFICIENCY
    * INOZYME PHARMA INC - PRELIMINARY BIOMARKER AND SAFETY DATA
FROM
PHASE 1/2 CLINICAL TRIAL IN ABCC6 DEFICIENCY EXPECTED IN Q2 OF
2022
    * INOZYME PHARMA INC - SECOND COHORT IN PHASE 1/2 CLINICAL
TRIAL
IN ENPP1 DEFICIENCY FULLY ENROLLED; TOPLINE DATA EXPECTED IN
SECOND HALF OF 2022

Source text for Eikon:  ID:nGNX75KnbS 
Further company coverage:  INZY.O 

 ((Reuters.Briefs@thomsonreuters.com;))